What is the endocannabinoid system?

The endocannabinoid system (ECS) is a biological retrograde signalling system comprising a broad network of lipid-based chemical signals, cellular receptors, and enzymes distributed throughout the central nervous system (CNS) and peripheral tissues. It plays a central role in regulating and maintaining balance across numerous physiological processes, including immune response, intercellular communication, sleep, pain, appetite, hormone levels, metabolism, and memory.

‍

The ECS is composed of three core components, each described in detail below:
‍

• Endogenous cannabinoids (endocannabinoids)
• Cannabinoid receptors
• Enzymes responsible for the synthesis and degradation of endocannabinoids

Unlike the nervous or cardiovascular systems, the ECS is not anatomically isolated to a specific region. It is a receptor system broadly distributed throughout the brain, organs, connective tissues, glands, and immune cells.

What is the role of the endocannabinoid system?

The ECS plays a vital role in both the CNS and immune system. Researchers have linked it to at least 15 distinct physiological processes:^1
‍

• Appetite and digestion
• Bone remodelling and growth
• Cardiovascular system function
• Chronic pain
• Inflammation and immune response
• Learning and memory
• Liver function
• Metabolism
• Mood
• Motor control
• Muscle formation
• Reproductive system function
• Skin and nerve function
• Sleep
• Stress

These functions collectively contribute to the stability of a patient’s internal environment. The primary role of the ECS is to restore homeostasis when external forces — such as injury, illness, or physiological stressors — disrupt normal function.
‍

The three core components of the ECS work in concert to keep these processes in balance. Each is described individually below.

1. Endogenous cannabinoids (endocannabinoids)

Endocannabinoids are naturally occurring lipid-based molecules produced by the body. They mediate normal physiological function and appear to have evolved in the brain to maintain biological homeostasis, as well as to support neuronal plasticity.
‍

The two major endocannabinoids identified to date are:
‍

• Anandamide (AEA)
• 2-Arachidonoyl glycerol (2-AG)

Both are produced on demand and support normal physiological function. Deficiency or dysregulation of endocannabinoid production may necessitate external approaches to upregulate ECS activity.
‍

Endocannabinoids should not be confused with phytocannabinoids, which are derived from plants. Phytocannabinoids occur naturally across a range of plant species but are most concentrated in cannabis. Well-known examples include CBD and THC, though hundreds of cannabinoids have been identified.

2. Cannabinoid receptors

Cannabinoid receptors are expressed on the surface of cells throughout the body. When endocannabinoids bind to these receptors, the ECS initiates a regulatory response. Two primary receptor subtypes have been identified:^1
‍

• CB1 receptor — predominantly expressed in the CNS, brain, connective tissues, gonads, glands, and organs. CB1 receptors are the primary binding site for THC, which accounts for its psychoactive effects.
• CB2 receptor — predominantly expressed in immune tissues and cells involved in immune response.

Many tissues co-express both receptor subtypes, each linked to distinct downstream actions. Both endocannabinoids (AEA and 2-AG) and phytocannabinoids (THC and CBD) interact with CB1 and CB2 receptors to produce varying physiological effects.

3. Enzymes

Enzymes within the ECS are responsible for the synthesis and degradation of endocannabinoids.² Specific enzymes produce endocannabinoids on demand; once those endocannabinoids have fulfilled their function, separate enzymes rapidly degrade them to prevent over-correction and maintain physiological balance.
‍

The two primary degradative enzymes are:
‍

• Fatty acid amide hydrolase (FAAH) — responsible for the breakdown of anandamide (AEA)
• Monoacylglycerol acid lipase (MAGL) — responsible for the breakdown of 2-arachidonoyl glycerol (2-AG)

Modulation of these enzymes can upregulate or downregulate the ECS by altering endocannabinoid concentrations within the body.

How does the endocannabinoid system work?

The ECS operates through postsynaptic retrograde signalling. Unlike classical neurotransmitters, which are synthesised and stored in vesicles prior to release, endocannabinoids are produced on demand. They are released from postsynaptic neurons and bind to cannabinoid receptors on presynaptic neurons, modulating neurotransmitter release and producing regulatory feedback.
‍

This signalling occurs throughout the CNS and peripheral tissues, supporting the regulation of mood, pain, inflammation, digestion, sleep, and numerous other physiological functions.
‍

In practical terms: when a system is dysregulated, endocannabinoids bind to receptors to help correct the imbalance. Once homeostasis is restored, enzymes degrade the endocannabinoids to prevent overcorrection.

The endocannabinoid system and pain

In the context of pain, a nociceptive signal may trigger the synthesis of 2-AG, which then binds to and activates CB1 and/or CB2 receptors³ to modulate pain perception⁴ without disrupting other physiological processes such as temperature regulation or digestion. Once balance is restored, MAGL rapidly degrades 2-AG to prevent ECS overcorrection.

‍

In conditions characterised by chronic or treatment-resistant symptoms — such as chronic pain, anxiety, or inflammatory disease — where the ECS has failed to restore homeostasis, endocannabinoid deficiency or ECS dysregulation may be a contributing factor worth investigating.

How does medicinal cannabis interact with the endocannabinoid system?

Cannabis contains hundreds of cannabinoids, the most clinically significant of which are CBD, THC, CBN, CBC, and CBG. Because phytocannabinoids share structural similarities with endocannabinoids, they have the potential to interact with ECS receptors and modulate physiological function in some patients.
‍

THC and the endocannabinoid system

THC acts directly on the ECS by binding to and activating CB1 receptors, producing a psychoactive effect. Clinically, this may translate to analgesia, antiemesis, appetite stimulation, and sleep improvement in some patients.

‍

Because THC acts directly on CB1 receptors, excessive dosing can flood these receptors and lead to ECS dysregulation, potentially resulting in increased anxiety, impaired memory, and slowed reaction time. Individualised treatment planning and careful dose titration are therefore essential when prescribing THC-containing formulations.

‍

CBD and the endocannabinoid system

CBD acts indirectly on the ECS, interacting with opioid, dopamine, and serotonin receptors. This gives it potential utility in pain, depression, and anxiety management, as well as possible immunomodulatory effects and potential applications in addiction management.

‍

CBD is more likely to bind to CB2 receptors than CB1. It is also considered an allosteric modulator of both CB1 and CB2 — meaning rather than binding to the active receptor site, it attaches to an alternative site and modifies receptor conformation, thereby modulating receptor activity. This mechanism accounts for the absence of intoxicating effects with CBD.

‍

CBD has also been found to inhibit the activity of FAAH,⁵ the enzyme responsible for degrading anandamide (AEA). Given anandamide’s role in mood, memory, appetite, sleep, and pain modulation, CBD’s inhibition of its degradation may support these functions and contribute to its anxiolytic and analgesic properties.

‍

CBN and the endocannabinoid system

Cannabinol (CBN) is a minor cannabinoid produced through the degradation of THC. It has demonstrated anticonvulsant, sedative, and other pharmacological activities that are still under investigation.⁶

‍

Like THC, CBN binds to CB1 receptors, though with lower affinity.⁶ While technically psychoactive, it does not produce the intoxicating effects associated with THC. CBN has a stronger affinity for CB2 receptors, which are primarily associated with immune system regulation.

Clinical endocannabinoid deficiency

Clinical Endocannabinoid Deficiency (CECD) is a theoretical framework proposed by neuropharmacologist Dr Ethan Russo to explain the potential therapeutic utility of cannabis in certain treatment-resistant conditions.⁷

‍

The theory holds that reduced endocannabinoid tone — whether due to low endocannabinoid levels, excess metabolic enzyme activity, or other ECS dysfunction — may contribute to the development of chronic conditions including:
‍

• Irritable bowel syndrome⁸
• Fibromyalgia⁸
• Chronic migraines⁸
• Endometriosis⁹
• Anxiety disorders¹⁰
• Depression¹¹
• PTSD¹²
• Autism spectrum disorder¹³

A 2016 review of over a decade of ECS research suggested that endocannabinoid deficiency may help explain why some patients develop IBS, fibromyalgia, and chronic migraine.⁸ It is important to note that CECD remains a theoretical construct and has not yet achieved formal clinical consensus. More robust research is needed before definitive conclusions can be drawn.

Possible indicators of endocannabinoid deficiency

Where a patient presents with treatment-resistant symptoms involving systems regulated by the ECS — such as chronic pain, sleep disturbance, menstrual pain, stress dysregulation, IBS, migraine, or mood disorders — ECS deficiency or dysregulation may be worth considering as a contributing factor. There is currently no definitive diagnostic test for CECD.

Is medicinal cannabis appropriate for my patient?

Medicinal cannabis may be worth considering for patients with chronic conditions whose symptoms have not responded adequately to standard treatments. Conditions associated with potential endocannabinoid dysfunction — including endometriosis and fibromyalgia — may be particularly relevant.

‍

A thorough assessment of the patient’s symptoms, the most clinically appropriate format and route of administration, and the optimal dose will inform which cannabinoids and phytochemical compounds are best suited to each individual patient.

‍

Supporting endocannabinoid system function: clinical considerations

A number of evidence-informed lifestyle and dietary interventions may help patients naturally support ECS function and address potential endocannabinoid deficiency:

‍

• Omega-3 fatty acid intake: fatty acid precursors found in omega-3 are known to support endocannabinoid production.¹⁴ Patients may benefit from increasing dietary intake of sources such as oily fish, nuts, seeds, and omega-3 enriched eggs.
• Gut microbiome diversity: a diet rich in varied fruits and vegetables provides prebiotic substrates that support gut microbiome diversity and may enhance endocannabinoid tone.¹⁵
• Terpene exposure: the terpene beta-caryophyllene (BCP), found in basil, black pepper, cloves, cinnamon, and cannabis, is a selective CB2 agonist¹⁶ with anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.
• Physical activity: exercise has been shown to increase endocannabinoid levels¹⁷ and support homeostasis. Moderate aerobic activity appears to confer greater benefit than light or high-intensity exercise.¹⁸
• Stress reduction: prolonged stress can impair cannabinoid receptor development and disrupt CB1 receptor function via elevated cortisol. Stress management strategies may therefore support ECS regulation.¹⁹
• Phytocannabinoid supplementation: where endocannabinoid deficiency is suspected⁸ or where chronic symptoms have not responded to standard treatment, medicinal cannabis may support ECS function via exogenous cannabinoid activity.

Clinical Summary

The endocannabinoid system plays a critical role in CNS and immune function, and maintaining ECS balance is fundamental to a broad range of physiological processes. Lifestyle interventions including dietary modification, physical activity, and stress reduction can support ECS upregulation.

‍

Where these approaches are insufficient — particularly in the context of chronic, treatment-resistant conditions — phytocannabinoids such as THC and CBD may offer clinically meaningful benefit by augmenting endocannabinoid tone and modulating receptor activity.